Measuring care needs and case-mix by means of the INTERMED

de Jonge, P.; Huyse, F.J.; Stiefel, F.C.

Published in:
General Hospital Psychiatry: Psychiatry, Medicine and Primary Care

Publication date:
2001

Link to publication

Citation for published version (APA):
published in your Journal [1]. The authors suggest that 27% of the eating disorders patients meet criteria for seasonal affective disorder (SAD).

Serotonergic system plays an important part in feeding regulation [2] and several lines of evidence suggest that serotonergic system is involved in the pathogenesis of SAD [3]. Thus, researchers focus on determining whether variants of genes related to serotonergic transmission are associated with SAD and eating disorders.

We have recently reported an association between the −1438G/A promoter polymorphism of the 5-HT2A gene and SAD [4]. We found a significant increase in the frequency of the −1438A variant allele of the 5-HT2A promoter polymorphism in SAD patients compared to low-seasonal controls. The difference in genotype distribution was also significant.

Many, but not all studies have found an association between the −1438G/A 5-HT2A polymorphism and eating disorders. This association has been reported by Collier et al. [5], Sorbi et al. [6], Enoch et al. [7], Nachmias et al. [8] but not by Hinney et al. [9], Campbell et al. [10], Ziegler et al. [11]. Despite the discrepant results of the studies it is very possible that the −1438G/A promoter polymorphism of the 5-HT2A gene plays a role in the development of eating disorders.

Levitan et al. [12] have recently reported preliminary results of their ongoing study. The authors suggest that variation of the tryptophan hydroxylase gene may play a role in eating behavior and weight regulation in females with SAD.

Thus, it is possible that there is a genetic link between SAD and eating disorders. It is interesting to speculate that there are specific inherited personality types with a predisposition to both eating disorders and SAD. Obsessional, perfectionistic, and anxious personality traits may contribute to the pathogenesis of eating disorders and SAD.
Studies of patients with chronic low back pain and diabetes suggested that patients identified by the INTERMED as being biopsychosocially complex responded not as well, by far, to standard biomedical treatment than the less complex patients. We will now evaluate in prospective intervention studies whether these complex patients will benefit from multi-modal treatments, consisting of somatic, psychiatric and social care.

The delivery of health care in real world settings, as Katon mentioned, should be focused on individual care needs. For this goal, the INTERMED can be used as a clinical decision-making tool. In order to assess the effectiveness of treatments in real world settings, the INTERMED can be used to control for confounding variables and designing multimodal treatment.

Peter de Jonge, Ph.D.
Frits J. Huysse, M.D., Ph.D.
C-L Psychiatry Service,
VU Hospital,
P.O. Box 7057,
1007 MB Amsterdam,
The Netherlands
E-mail address: p.dejonge@azvu.nl
Friedrich C. Stiefel, M.D.
C-L Psychiatry Service,
University Hospital,
Lausanne, Switzerland

PII: S0163-8343(00)00108-0

References

Dermatologic presentation of panic disorder

To the Editor:

Several investigators have suggested a classification system for panic disorder based upon predominant symptom clusters. In this regard, Bouwer and Stein [1] classified patients according to cardiovascular, respiratory, gastrointestinal, and oculovestibular symptoms. Other investigators have described depersonalization-derealization [2], derealization [3], and cognitive [4] subtypes of panic. Whether these symptom-based subtypes demonstrate epidemiologic, etiologic, or treatment differences remains unknown. However, among some individuals, panic disorder appears to present as specific and predominant clusters of somatic and psychological symptoms. We wish to report a case of panic disorder that was highlighted by dermatologic symptoms.

Case report

A 19-year old, white male presented to the outpatient internal medicine clinic for evaluation of an intermittent rash which had been occurring over the past 6 weeks, up to 2 to 3 times per day, and lasting 10 to 15 minutes. The rash initially emerged on the patient’s chest and back, and promptly extended to all extremities. The rash was pruritic, maculopapular (1–2 mm), erythematous, non-vesicular, and non-urticarial, and described as “pins and needles” in sensation. Adjunctive symptoms included tachycardia, feelings of “disorientation,” inability to focus, and restlessness. The patient denied dyspnea, nausea, dizziness, diaphoresis, perceptual disturbances, diarrhea, or headaches. The symptoms began after the termination of a significant relationship and were subsequently triggered by various emotional precipitants. With each outbreak, the patient would “talk himself down,” physically relocate himself, shower, chew gum, or place his hands in cold water. He expressed his social concern about the visibility of the rash, stating that coworkers had commented upon his dramatic symptoms.

During initial consultation with his primary care physician, the patient developed the rash while waiting in the examination room. Vital signs including blood pressure were normal. Laboratory studies indicated no eosinophilia or thyroid abnormalities. The patient was started on cetirizine and paroxetine beginning at 5 mg per day.

During psychiatric consultation 10 days later, the patient reported no prior mental health exposure, but acknowledged a history of low-grade anxiety and a “panic attack” in the 6th grade which was not accompanied by dermatologic symptoms. He described himself as a “worryer” by nature and had been placed on fluoxetine during mid-adolescence by a primary care physician for the treatment of anxiety. The family history included substance abuse, antidepressant exposure, and one suicide, but no panic disorder. The dose of paroxetine was gradually titrated to 30 mg per day and at a follow-up visit 4 weeks into treatment, the patient experienced complete remission of all symptoms.

* Corresponding author. Sycamore Primary Care Center, 2115 Leiter Road, Miamisburg, Ohio 45342. Tel.: +1-937-384-6850; fax: +1-937-384-6938.
E-mail address: specg.kethealth.com (R.A. Sansone).